AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29759576 — intervention group
Group type: EXPERIMENTAL
Intervention: Period of <3 years since MI (lowest quartile, n = 172)
Number of subjects: 693
Study 29759576 — intervention group
Group type: COMPARATOR
Intervention: Period of ≥3 years since MI (n = 521)
Number of subjects: 693
Study 29759576 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with LBBB and period of ≥3 years since MI
Number of subjects: 693
Study 29759606 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 192
Study 29759618 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic MRI-conditional pacing system
Number of subjects: 2629
Study 29759624 — intervention group
Group type: EXPERIMENTAL
Intervention: Long detection programming (30 of 40 intervals)
Number of subjects: 545
Study 29759624 — intervention group
Group type: COMPARATOR
Intervention: Standard programming (18 of 24 intervals)
Number of subjects: 545
Study 29759624 — intervention group
Group type: EXPERIMENTAL
Intervention: Long detection programming
Number of subjects: 545
Study 29759747 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter stability with CF applied ≥73% of the time within the preselected CF range
Number of subjects: 0
Study 29759747 — intervention group
Group type: EXPERIMENTAL
Intervention: Average CF categories of 0 to 10 g
Number of subjects: 0
Study 29759747 — intervention group
Group type: EXPERIMENTAL
Intervention: Average CF categories of 10 to 20 g
Number of subjects: 0
Study 29759747 — intervention group
Group type: EXPERIMENTAL
Intervention: Average CF categories of >20 g
Number of subjects: 0
Study 29759747 — intervention group
Group type: EXPERIMENTAL
Intervention: CF of 6.5 to 10.3 g
Number of subjects: 0
Study 29759747 — intervention group
Group type: EXPERIMENTAL
Intervention: PV gaps exceeding 10.6-mm distance
Number of subjects: 0
Study 29759834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 151
Study 29759834 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty (defined as G8 score <14)
Number of subjects: 151
Study 29759834 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty
Number of subjects: 151
Study 29759834 — intervention group
Group type: EXPERIMENTAL
Intervention: G8 score <10.25
Number of subjects: 151
Study 29759838 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor (ICM)
Number of subjects: 82
Study 29759838 — intervention group
Group type: COMPARATOR
Intervention: 72-h Holter monitoring
Number of subjects: 82
Study 29759864 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD or CRT-D in black patients
Number of subjects: 1777
Study 29759864 — intervention group
Group type: COMPARATOR
Intervention: ICD or CRT-D in white patients
Number of subjects: 1777
Study 29759903 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis for digestive disorders with omeprazole
Number of subjects: 419
Study 29759903 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis with omeprazole (Control)
Number of subjects: 419
Study 29759953 — intervention group
Group type: EXPERIMENTAL
Intervention: Life in a Day mobile phone app
Number of subjects: 40
Study 29759957 — intervention group
Group type: EXPERIMENTAL
Intervention: MORPH intervention (12-week duration)
Number of subjects: 30
Study 29759957 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 30
Study 29760012 — intervention group
Group type: EXPERIMENTAL
Intervention: Core laboratory scores for ASPECTS
Number of subjects: 0
Study 29760012 — intervention group
Group type: EXPERIMENTAL
Intervention: Core laboratory scores for ECASS HT classification
Number of subjects: 0
Study 29760012 — intervention group
Group type: EXPERIMENTAL
Intervention: Core laboratory scores for TICI
Number of subjects: 0
Study 29760012 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotomized TICI score (TICI 0/1/2a vs 2b/3)
Number of subjects: 0
Study 29760012 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based scores
Number of subjects: 0
Study 29760012 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based scores
Number of subjects: 0
Study 29760162 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrelated cord blood transplantation (CBT)
Number of subjects: 26
Study 29760228 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0
Study 29760228 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or standard care not specified)
Number of subjects: 0
Study 29760559 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 4110
Study 29760559 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 4110
Study 29760559 — intervention group
Group type: EXPERIMENTAL
Intervention: Never smokers
Number of subjects: 4110
Study 29760737 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRC-enriched fat grafting (group I)
Number of subjects: 14
Study 29760737 — intervention group
Group type: COMPARATOR
Intervention: Centrifuged autologous fat (CAF) grafts (group II)
Number of subjects: 14
Study 29760763 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (5, 10, or 20 mg)
Number of subjects: 27
Study 29761174 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR) 50 mg/100 mg once daily for 12 weeks
Number of subjects: 337
Study 29761174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study 29761174 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR)
Number of subjects: 337
Study 29761420 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily
Number of subjects: 0
Study 29761420 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib or MTX with CDAI remission or low disease activity (LDA) at month 6
Number of subjects: 0
Study 29761420 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 0
Study 29761420 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 0
Study 29761785 — intervention group
Group type: EXPERIMENTAL
Intervention: cardiac glycoside reductase
Number of subjects: 0
Study 29761903 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ABC294640 (sphingosine kinase 2 inhibitor) and ABT-199 (Bcl-2 inhibitor)
Number of subjects: 0
Study 29761903 — intervention group
Group type: COMPARATOR
Intervention: ABT-199 (Bcl-2 inhibitor)
Number of subjects: 0
Study 29761903 — intervention group
Group type: COMPARATOR
Intervention: ABC294640 (sphingosine kinase 2 inhibitor)
Number of subjects: 0
Study 29762444 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma injection
Number of subjects: 17
Study 29762532 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimester-specific air pollution exposure (divided into quartiles Q1⁻4)
Number of subjects: 0
Study 29762717 — intervention group
Group type: EXPERIMENTAL
Intervention: Toca 511 + Toca FC
Number of subjects: 56
Study 29762769 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for traumatic ASDH in younger patients
Number of subjects: 0
Study 29762769 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for traumatic ASDH in elderly patients (≥70 yr)
Number of subjects: 0
Study 29762769 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for traumatic ASDH in both younger and elderly patients
Number of subjects: 0
Study 29763980 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA) group (N=40)
Number of subjects: 71
Study 29763980 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=31)
Number of subjects: 71
Study 29764238 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 695501 via autoinjector (AI)
Number of subjects: 77
Study 29764386 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed clinical examination by a movement disorder specialist
Number of subjects: 0
Study 29764386 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) techniques
Number of subjects: 0
Study 29764386 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) biomarkers
Number of subjects: 0
Study 29764550 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid challenge
Number of subjects: 40
Study 29764716 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized-Targeted Computerized Cognitive Training
Number of subjects: 0
Study 29764869 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-UPCAT (AOT at home for 3 weeks)
Number of subjects: 24
Study 29764869 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group for 3 weeks)
Number of subjects: 24
Study 29764875 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose GHX02 (1920 mg/day)
Number of subjects: 150
Study 29764875 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose GHX02 (960 mg/day)
Number of subjects: 150
Study 29764875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 29764880 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital breast tomosynthesis plus synthesised images (DBT+s2D)
Number of subjects: 80000
Study 29764880 — intervention group
Group type: COMPARATOR
Intervention: Standard full-field digital mammography (FFDM)
Number of subjects: 80000
Study 29764889 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous cultured mesenchymal stem cells (MSCs) implanted into the area of mid-portion AT.
Number of subjects: 10
Study 29764892 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised high-intensity aerobic and resistance exercise
Number of subjects: 866
Study 29764892 — intervention group
Group type: COMPARATOR
Intervention: Self-directed exercise (provision of guidelines)
Number of subjects: 866
Study 29764958 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (DM)
Number of subjects: 0
Study 29764958 — intervention group
Group type: COMPARATOR
Intervention: No diabetes mellitus (Control group)
Number of subjects: 0
Study 29765401 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF) training, 15 double training sessions
Number of subjects: 48
Study 29765616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative steroid exposure (dose and duration) categorized into four levels: 0g (no exposure), >0 and <3.65g (<10mg/day for a year), ≥3.65g and <18.25g (1-5 years at 10mg/day), and ≥18.25g (>5 years at 10mg/day).
Number of subjects: 409
Study 29766026 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal AAV9 Gene Therapy
Number of subjects: 0
Study 29766087 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive fascial closure of the laparotomy
Number of subjects: 0
Study 29766087 — intervention group
Group type: COMPARATOR
Intervention: Damage control laparotomy (DCL)
Number of subjects: 0
Study 29766088 — intervention group
Group type: EXPERIMENTAL
Intervention: Community consultation (CC) process using random digit dialing technique
Number of subjects: 500
Study 29766134 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy with intraoperative cholangiogram (IOC) at index admission within 24 hours of presentation
Number of subjects: 0
Study 29766134 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy with intraoperative cholangiogram (IOC) after clinical resolution
Number of subjects: 0
Study 29766216 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEi/ARB at ICU discharge
Number of subjects: 1551
Study 29766216 — intervention group
Group type: COMPARATOR
Intervention: No ACEi/ARB at ICU discharge
Number of subjects: 1551
Study 29766308 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic TAPP (r-TAPP)
Number of subjects: 50
Study 29766308 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic TAPP (l-TAPP)
Number of subjects: 50
Study 29766322 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular Flow Index (MFI) < 2.6
Number of subjects: 97
Study 29766322 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal MFI on day 1
Number of subjects: 97
Study 29766322 — intervention group
Group type: COMPARATOR
Intervention: Routine daily microcirculatory monitoring
Number of subjects: 97
Study 29766337 — intervention group
Group type: EXPERIMENTAL
Intervention: ASLAN-002 at 300 mg BID
Number of subjects: 40
Study 29766337 — intervention group
Group type: EXPERIMENTAL
Intervention: ASLAN-002 at 450 mg BID
Number of subjects: 40
Study 29766337 — intervention group
Group type: EXPERIMENTAL
Intervention: ASLAN-002 (all doses)
Number of subjects: 40
Study 29766383 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insufficiency
Number of subjects: 0
Study 29766456 — intervention group
Group type: EXPERIMENTAL
Intervention: dNLR ≥ 1.35 in hormone receptor-negative/HER2+ population
Number of subjects: 1246
Study 29766456 — intervention group
Group type: EXPERIMENTAL
Intervention: dNLR ≥ 1.35 in patients with one to three lymph node metastases
Number of subjects: 1246
Study 29766456 — intervention group
Group type: EXPERIMENTAL
Intervention: dNLR in non-luminal tumors
Number of subjects: 1246
Study 29766456 — intervention group
Group type: EXPERIMENTAL
Intervention: dNLR in HER2-enriched tumors
Number of subjects: 1246
Study 29766812 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofogliflozin
Number of subjects: 19
Study 29766854 — intervention group
Group type: EXPERIMENTAL
Intervention: Basket catheter deployment
Number of subjects: 25
Study 29766854 — intervention group
Group type: EXPERIMENTAL
Intervention: Basket catheter peak-to-peak voltage measurement
Number of subjects: 25
Study 29766854 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrogram stability and organization
Number of subjects: 25
Study 29766854 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment of basket catheters
Number of subjects: 25
Study 29766871 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 418
Study 29766871 — intervention group
Group type: COMPARATOR
Intervention: Fludrocortisone
Number of subjects: 418
Study 29766871 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both metoprolol and fludrocortisone)
Number of subjects: 418
Study 29766871 — intervention group
Group type: COMPARATOR
Intervention: General driving population (U.S., U.K., Canada)
Number of subjects: 418
Study 29766873 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadripolar CRT system (Quartet LV lead)
Number of subjects: 1078
Study 29766873 — intervention group
Group type: COMPARATOR
Intervention: Bipolar CRT lead system (BiP group)
Number of subjects: 1078
Study 29766891 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous heparin infusion
Number of subjects: 333
Study 29766891 — intervention group
Group type: COMPARATOR
Intervention: Intermittent heparin infusion
Number of subjects: 333
Study 29766891 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients on NOACs
Number of subjects: 333
Study 29766891 — intervention group
Group type: COMPARATOR
Intervention: Patients on warfarin
Number of subjects: 333
Study 29766894 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD lead monitoring during LVAD implantation
Number of subjects: 32
Study 29767680 — intervention group
Group type: COMPARATOR
Intervention: African-American women
Number of subjects: 66
Study 29767680 — intervention group
Group type: COMPARATOR
Intervention: Physical activity, substrate oxidation, and metabolic biomarkers
Number of subjects: 66
Study 29767732 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of α-linolenic acid (ALA)
Number of subjects: 57053
Study 29767735 — intervention group
Group type: EXPERIMENTAL
Intervention: Banana and dopamine 3-O-sulfate
Number of subjects: 1369
Study 29767735 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 4-O-sulfate
Number of subjects: 1369
Study 29767735 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic and alliin
Number of subjects: 1369
Study 29767735 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylalliin
Number of subjects: 1369
Study 29767735 — intervention group
Group type: EXPERIMENTAL
Intervention: S-allylcysteine
Number of subjects: 1369
Study 29767735 — intervention group
Group type: EXPERIMENTAL
Intervention: Unannotated metabolite X-02269 for dark fish intake
Number of subjects: 1369
Study 29767735 — intervention group
Group type: EXPERIMENTAL
Intervention: Unannotated metabolite X-21442 for coffee intake
Number of subjects: 1369
Study 29767845 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide treatment after HSCT
Number of subjects: 1000
Study 29767845 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide treatment in paediatric patients
Number of subjects: 1000
Study 29767845 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide treatment in adult patients
Number of subjects: 1000
Study 29767845 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide treatment without multi-organ dysfunction (MOD)
Number of subjects: 1000
Study 29767845 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier initiation of defibrotide treatment after VOD/SOS diagnosis
Number of subjects: 1000
Study 29768274 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated quantitative conjunctival provocation test (CPT)
Number of subjects: 23
Study 29768372 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention program including wearable devices, App for recording activities, counseling, physical activity program, and pelvic floor treatment.
Number of subjects: 0
Study 29768438 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI ≥25.1 kg/m2
Number of subjects: 2833
Study 29768438 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI >25.1 kg/m2 in male patients
Number of subjects: 2833
Study 29768438 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased BMI after 12 months and high serum creatinine
Number of subjects: 2833
Study 29768438 — intervention group
Group type: COMPARATOR
Intervention: Baseline and follow-up BMI in female patients
Number of subjects: 2833
Study 29768645 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic resection of LSL-P
Number of subjects: 125
Study 29768645 — intervention group
Group type: COMPARATOR
Intervention: Ampullary adenomas
Number of subjects: 125
Study 29769025 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine culture performed in practice
Number of subjects: 488
Study 29769025 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine culture performed at hospital
Number of subjects: 488
Study 29769025 — intervention group
Group type: COMPARATOR
Intervention: No culture performed
Number of subjects: 488
Study 29769049 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for sleep-disordered breathing (SDB) using a two-channel screening system (ApneaLink™)
Number of subjects: 100
Study 29769049 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with moderate to severe SDB
Number of subjects: 100
Study 29769049 — intervention group
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI) assessment
Number of subjects: 100
Study 29769127 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic indices provided by a novel robotic device for upper limb rehabilitation
Number of subjects: 48
Study 29769174 — intervention group
Group type: EXPERIMENTAL
Intervention: Lark (virtual coaching app with JITAI features)
Number of subjects: 0
Study 29769174 — intervention group
Group type: COMPARATOR
Intervention: MyFitnessPal (self-help calorie-counting app)
Number of subjects: 0
Study 29769232 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compression-decompression (ACD) CPR
Number of subjects: 10
Study 29769232 — intervention group
Group type: COMPARATOR
Intervention: Manual CPR
Number of subjects: 10
Study 29769232 — intervention group
Group type: EXPERIMENTAL
Intervention: ACD-CPR and Manual CPR
Number of subjects: 10
Study 29769385 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus Irinotecan (Pa 9 mg/m)
Number of subjects: 18
Study 29770461 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous motivation
Number of subjects: 136
Study 29770461 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled motivation
Number of subjects: 136
Study 29770461 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 136
Study 29770625 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop electrosurgical excision procedure/conization
Number of subjects: 69741
Study 29770625 — intervention group
Group type: COMPARATOR
Intervention: Various management strategies (colposcopy, cervical biopsies and/or endocervical curettage, cryotherapy)
Number of subjects: 69741
Study 29770625 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous screening history >5 years from present ASCUS diagnosis
Number of subjects: 69741
Study 29770625 — intervention group
Group type: COMPARATOR
Intervention: Repeat cervical smears
Number of subjects: 69741
Study 29770748 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL) therapy for 8 weeks
Number of subjects: 22
Study 29770748 — intervention group
Group type: COMPARATOR
Intervention: Control (unchanged cART regimen) for 8 weeks
Number of subjects: 22
Study 29771158 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoker (SMK)
Number of subjects: 120
Study 29771158 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist Snuff Consumer (MSC)
Number of subjects: 120
Study 29771158 — intervention group
Group type: COMPARATOR
Intervention: Non-Tobacco Consumer (NTC)
Number of subjects: 120
Study 29771283 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk adolescents consuming high-sugar milkshake
Number of subjects: 108
Study 29771283 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk adolescents consuming milkshakes (all variants)
Number of subjects: 108
Study 29771283 — intervention group
Group type: COMPARATOR
Intervention: Low-risk adolescents consuming milkshakes (all variants)
Number of subjects: 108
Study 29771283 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat milkshake
Number of subjects: 108
Study 29771289 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma trigonelline concentrations after coffee consumption
Number of subjects: 3503
Study 29771289 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma trigonelline as a marker of coffee intake
Number of subjects: 3503
Study 29771289 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-person reproducibility of plasma trigonelline
Number of subjects: 3503
Study 29771289 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee consumption and plasma concentrations of niacin vitamers
Number of subjects: 3503
Study 29773527 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled SMS
Number of subjects: 63
Study 29773527 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS triggered by missed or delayed doses
Number of subjects: 63